No Data
Is Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Using Too Much Debt?
Zhangzhou Pientzehuang Pharmaceutical's (SHSE:600436) Five-year Total Shareholder Returns Outpace the Underlying Earnings Growth
The growing anxiety of Chiyao Mao
Where is the new way out?
Zhangzhou pientzehuang pharmaceutical "curved" acquisition of Fujian cosunter pharmaceutical? The innovative drugs sector sees the reappearance of traditional chinese medicine industry players | Read the announcement quickly.
Fujian Cosunter Pharmaceutical announced that the Yuanshan Fund intends to become a shareholder with more than 5% stake in the company through a transfer payment of nearly 0.2 billion yuan. The partners of the Yuanshan Fund consist of a wholly state-owned company and a wholly-owned subsidiary of zhangzhou pientzehuang pharmaceutical, among which the investment from zhangzhou pientzehuang pharmaceutical is the largest limited partner in the fund.
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Stock Is Going Strong: Is the Market Following Fundamentals?
Zheshang: The new batch of national chinese patent medicine centralized procurement overall meets expectations. Focus on related traditional chinese medicine symbols.
With the continuous expansion of the centralized procurement categories, large varieties of listed companies, especially large non-exclusive varieties, may be included in the new batch procurement catalogue.
102884128 : getting disappointed with this counter. every day drop.